We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

By LabMedica International staff writers
Posted on 15 Apr 2024

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells. More...

However, traditional cell separation techniques, which typically focus on isolating single tumor cells, are inadequate for simultaneously purifying tumor cell clusters. In response, researchers have developed a microfluidic method capable of high-throughput, continuous-flow ternary separation of single tumor cells, tumor cell clusters, and white blood cells (WBCs) from clinical samples of pleural or abdominal effusions. This technique incorporates slanted spiral channels and periodic contraction-expansion arrays to achieve separation.

The novel spiral-contraction-expansion device developed by researchers from Southeast University (Nanjing, China) utilizes slanted spiral channels combined with periodic contraction-expansion arrays for high-throughput, continuous-flow ternary separation of tumor cells and tumor cell clusters from a background of blood cells. By introducing periodic contraction-expansion arrays, the spiral-contraction-expansion device allows for the size-based ternary separation of cells under the combined action of the inertial lift force, Dean drag force, and local vortex-induced lift force. The researchers first characterized the ternary inertial focusing of differently sized particles in their spiral-contraction-expansion device and optimized the operational flow rate.

Subsequent evaluation was conducted of the device’s separation performance, recovery ratio, and purity of the tumor cells and clusters. The researchers also examined the device’s ability to carry out ternary separation of exfoliated tumor cells, tumor cell clusters, and WBCs from clinical pleural or abdominal effusions derived from cancer patients. The spiral-contraction-expansion device provides numerous benefits, including label-free, continuous-flow, high-throughput separation of tumor cells and clusters from cancer patient effusions in a single step. This method offers significant potential for enhancing the diagnosis and monitoring of treatment in cancer patients by analyzing malignant effusions with higher precision and efficiency.

Related Links:
Southeast University


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.